Neuroinflammation: molecular mechanisms, triggers, and biomarkers for clinical stratification

Abstract

Neuroinflammation is increasingly regarded as a key factor in the progression of neurological disorders. At the same time, in clinical practice it is often interpreted in an overly simplified manner and reduced to nonspecific activation of inflammatory responses.

Objective: to integrate contemporary molecular and cellular evidence in order to conceptualize neuroinflammation as a context-dependent and stage-determined biological program, and to delineate mechanistic determinants relevant to biomarker interpretation and therapeutic stratification.

Materials and methods: A narrative analysis of contemporary experimental, translational, and clinical studies focusing on innate protective mechanisms of the central nervous system was performed. The review emphasizes PRR-mediated recognition of pathogen-associated and damage-associated molecular patterns, intracellular inflammatory signaling pathways (NF-κB, MAPK, JAK/STAT, inflammasome complexes), mechanisms of inflammatory termination and resolution, and the regulatory role of the blood–brain barrier (BBB). Particular attention was given to data on glial cell biology, neurovascular unit signaling, biomarker profiles in cerebrospinal fluid and blood, and disease-specific neuroinflammatory phenotypes.

Results: The synthesized data indicate that neuroinflammation is not a uniform pathological state but represents a dynamic, multicomponent program shaped by the balance between initiation, amplification, resolution, and chronic persistence of inflammatory responses. Two closely interrelated components can be distinguished. The first is a resident innate neuroinflammatory program, predominantly mediated by microglia, astrocytes, and endothelial cells through PRR-dependent protective signaling mechanisms. The second is an adaptive immune component characterized by infiltration of peripheral immune cells and the development of antigen-specific responses. Disruption of resolution mechanisms, insufficient clearance of damage-associated signals, and sustained PRR activation promote the development of chronic neuroinflammation and neurodegenerative changes. The functional state of the BBB emerges as a critical modifier of neuroinflammatory dynamics, directly affecting biomarker interpretation, therapeutic access and clinical response.

Conclusions: Neuroinflammation should be conceptualized as a potentially modifiable biological program rather than a fixed pathological entity. Effective diagnostic and therapeutic strategies require context- and stage-specific stratification that takes into account the dominant inflammatory component, disease phase, etiological triggers, and the functional state of the BBB. Approaches aimed at limiting inflammatory amplification, restoring resolution mechanisms, and stabilizing barrier function are likely to offer greater translational potential than nonspecific anti-inflammatory suppression.